AbbVie Inc

Most Recent

  • uploads///Cosentyx
    Company & Industry Overviews

    How Is Novartis’s Cosentyx Positioned after 4Q17?

    In 4Q17, Novartis’s (NVS) Cosentyx generated revenues of $615 million compared to $391 million in 4Q16, which reflected ~57% growth on a year-over-year (or YoY) basis and ~11% growth quarter-over-quarter.

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    What Analysts Recommend for Novartis in March 2018

    As discussed earlier, Novartis (NVS) reported EPS (earnings per share) of $1.21 on revenues of $12.9 billion during 4Q17.

    By Mike Benson
  • uploads///ABBV
    Company & Industry Overviews

    Analyzing AbbVie’s Financial Performance

    AbbVie (ABBV) generated net revenue of $7.9 billion in 1Q18 compared to $6.5 billion in 1Q17.

    By Kenneth Smith
  • uploads///Chart
    Earnings Report

    Analysts’ Recommendations for Merck & Co. after 4Q17

    Merck & Co. (MRK) missed Wall Street analysts’ estimates for revenues but surpassed analysts’ estimates earnings per share.

    By Mike Benson
  • uploads///TSRO
    Company & Industry Overviews

    Gauging Analysts’ Views on Tesaro Stock

    In November, of the total 21 analysts covering Tesaro (TSRO) stock, 13 have given it “buy” or higher ratings, and eight have given it “hold” ratings.

    By Kenneth Smith
  • uploads///Chart
    Company & Industry Overviews

    Merck’s Valuation Cheat Sheet for Fiscal 1Q16

    Merck & Co.’s (MRK) current valuation is neither high nor low. Its valuation multiple has followed the industry’s overall trend over the last five years.

    By Mike Benson
  • uploads///Graph
    Earnings Report

    Amgen Continues to Control Operating Expenses in 3Q15

    In 3Q15, Amgen recorded total operating expenses of ~$3.4 billion. This fall in expenses enabled the company to report a net profit margin of ~36.4%.

    By Margaret Patrick
  • uploads///Biogen Analysts Recommendation
    Company & Industry Overviews

    What Analysts Recommend for Biogen in June 2017

    In 2016, Biogen (BIIB) reported revenues of $11.4 billion, which reflected a ~6% year-over-year (or YoY) growth.

    By Daniel Collins
  • uploads///Graph
    Earnings Report

    Venclexta Witnessed Healthy Demand Trends in 1Q17

    AbbVie’s (ABBV) Venclexta was approved by the FDA on April 11, 2016. AbbVie has also successfully launched Venclexta in Germany and France.

    By Margaret Patrick
  • uploads///MNK
    Fund Managers

    Adage Capital adds a new position in Mallinckrodt

    Adage Capital added a new position in Mallinckrodt Plc (MNK) in the third quarter of 2014. The position accounted for 0.82% of the fund’s total portfolio.

    By Samantha Nielson
  • uploads///Graph
    Earnings Report

    AbbVie’s Viekira Pak Saw Weaker-than-Expected Performance

    Viekira Pak managed to earn revenues worth about $414 million in 1Q16. The drug’s sales in the US market, however, fell YoY (year-over-year) by about 9.3% and reached $125 million in 1Q16.

    By Margaret Patrick
  • uploads///PFE MDVN deal
    Company & Industry Overviews

    What’s the Story behind the Pfizer-Medivation Deal?

    Medivation’s portfolio complements Pfizer’s existing oncology portfolio that includes solid tumors, hematology, and immunology-oncology.

    By Jillian Dabney
  • uploads///pill _
    Company & Industry Overviews

    Why Incyte Stock Fell ~9% on April 24

    On April 24, Incyte (INCY) stock fell ~9% on news regarding its drug Baricitinib, which is under FDA review.

    By Sarah Collins
  • uploads///Graph
    Earnings Report

    Biogen Pursuing Investigational Candidates in Alzheimer’s Disease

    Biogen (BIIB) has entered into a licensing agreement with Bristol-Myers Squibb (BMY) for exclusive global rights for the development and commercialization of BMS-986168.

    By Margaret Patrick
  • uploads///Yield Movement Before and During Taper Tantrum
    Macroeconomic Analysis

    What Should You Expect from Monetary Policy Announcements?

    Most FOMC participants indicated that they preferred to consider a possible rate hike on a meeting-by-meeting basis—without providing any hints about the timing of a rate hike.

    By David Ashworth
  • uploads///Graph
    Company & Industry Overviews

    AstraZeneca’s New Oncology Portfolio May See Healthy Growth

    In 1Q17, AstraZeneca’s (AZN) new oncology portfolio reported global sales of around $236.0 million. Tagrisso earned revenues of $171.0 million globally.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Gilead Sciences’ Product Line Extension

    As part of its significant product line extension, Gilead Sciences (GILD) is entering therapeutic areas such as oncology, pulmonology, and cardiology.

    By Margaret Patrick
  • uploads///Emend Temodar Revenues
    Company & Industry Overviews

    How Merck’s Oncology Drugs Emend and Temodar Could Perform in 2017

    In 2016, Merck’s (MRK) Emend reported revenues of around $549 million, which reflected 3% year-over-year growth.

    By Daniel Collins
  • uploads///syringe pill capsule morphine
    Earnings Report

    Seattle Genetics Posted Strong Q2 2018 Results, Stock Rose

    Seattle Genetics reported sales of $170.2 million in the second quarter, which represented 57.2% growth YoY (year-over-year).

    By Sarah Collins
  • uploads///Neuroscience
    Earnings Report

    Bristol-Myers Squibb’s Neuroscience and Immunoscience Segments

    Sales for Bristol-Myers Squibb’s (BMY) neuroscience segment declined over 80% in 2Q15, while the immunoscience segment’s sales improved ~15% in 2Q15 as compared to 2Q14.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Understanding Bristol-Myers Squibb’s Other Segments

    Sales from Bristol-Myers Squibb’s Neuroscience segment declined by 94% in 1Q16. Sales from the Immunoscience segment improved by ~18.7% in 1Q16 over 1Q15.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    AbbVie Hopes to Commercialize Next-Generation HCV Regimen by 2017

    AbbVie (ABBV) plans to complete its Phase 3 registrational program for investigational next-generation Hepatitis C virus (or HCV) therapy by 2016.

    By Margaret Patrick
  • uploads///PCYC ABBV ABBV basics
    Miscellaneous

    The Pharmacyclics–AbbVie Merger: The Basics of AbbVie

    A major reason for the Pharmacyclics–AbbVie merger is to diversify AbbVie away from its reliance on a single product, Humira, and boost its pipeline.

    By Brent Nyitray, CFA, MBA
  • uploads///Humira Revenues
    Company & Industry Overviews

    Humira May Continue to Drive AbbVie’s Revenue Growth

    In 2016, AbbVie’s (ABBV) drug Humira reported revenue of ~$16.0 billion, which reflected a ~15% year-over-year (or YoY) rise.

    By Daniel Collins
  • uploads///BioMarin Timeline
    Company & Industry Overviews

    Overview of BioMarin: History and Product Portfolio

    Here we present an overview of BioMarin. It’s based in California and was founded in 1997. It focuses on therapies for life-threatening rare genetic diseases.

    By Jillian Dabney
  • uploads///Graph
    Earnings Report

    Behind Celgene’s Blockbuster Revenue Hit in 4Q16

    In 2016, Celgene’s (CELG) Otezla attained blockbuster status by earning revenues in excess of $1 billion as a therapy for psoriasis and psoriatic arthritis.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    AbbVie Strengthens Its Position in the Virology Segment

    In addition to Humira, AbbVie also offers several virology drugs targeting diseases such as hepatitis C, HIV, and respiratory syncytial virus.

    By Margaret Patrick
  • uploads///Part
    Company & Industry Overviews

    Mylan’s Humira Biosimilar Opportunity in Europe

    On September 20, Mylan and its partner, Fujifilm Kyowa Kirin Biologics, received the marketing authorization from the European Commission for Hulio.

    By Sarah Collins
  • uploads///Graph
    Earnings Report

    Medicaid Restrictions Are Affecting Gilead’s Hepatitis C Drug Sales

    Since the launch of Sovaldi in late 2013, Gilead Sciences has managed to treat about 1,000,000 hepatitis C (or HCV) patients globally.

    By Margaret Patrick
  • uploads///Global Technology IPOs
    Company & Industry Overviews

    What Bob Doll Thinks about the IPO Market in 2017

    Equity market indexes across the United States are surging and recording all-time highs. The volatility index is also falling, which could be a good sign for IPO activity in 2017.

    By Mary Sadler
  • uploads///patents
    Company & Industry Overviews

    Why Is Enbrel So Important for Amgen?

    YTD, Amgen’s (AMGN) stock has already fallen 9%. Perhaps the pressure that Enbrel (etanercept) is seeing is to blame for the negative investor sentiment.

    By Jillian Dabney
  • uploads///Immunology Oncology
    Company & Industry Overviews

    A Look into Merck’s Immunology and Oncology Portfolio

    In 1H17, Remicade generated revenues of around $437 million, which is a 37% decline year-over-year.

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    Oncology Segment: Another Growth Platform for AstraZeneca?

    The oncology segment is another key focus area of AstraZeneca (AZN). The oncology segment’s contribution increased from ~11.6% in 2014 to ~12.1% in 2015.

    By Mike Benson
  • uploads///operating segments
    Earnings Report

    A Look at Mallinckrodt’s Operating Segments

    Mallinckrodt (MNK) is a specialty pharmaceuticals company that relies on volume-driven growth. Let’s discuss the performances of its three segments.

    By Jillian Dabney
  • uploads///Graph
    Miscellaneous

    FDA Granted Breakthrough Therapy Status to Merck’s HCV Therapy

    The U.S. Food and Drug Administration (or FDA) granted breakthrough therapy designation to Merck’s (MRK) grazoprevir/elbasvir (100mg/50mg) combination therapy.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Olumiant Could Boost Incyte’s Revenues

    In February 2017, Eli Lilly (LLY) secured approval for Olumiant (baricitinib) from the European Medicines Agency (or EMA) for patients suffering from moderate-to-severe rheumatoid arthritis.

    By Margaret Patrick
  • uploads///Oncology Franchise
    Company & Industry Overviews

    The Latest on TEVA’s Oncology Business

    In 1H17, Teva Pharmaceutical’s (TEVA) oncology business generated revenues of ~$550 million, or ~9% lower YoY (year-over-year).

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    Bristol-Myers Squibb: What Do Its Other Segments Offer?

    Bristol-Myers Squibb’s (BMY) neuroscience segment’s sales declined by 63.0% in 2015 from 2014, while its immunoscience segment’s sales improved ~14.1%.

    By Mike Benson
  • uploads///SHPG
    Fund Managers

    Shire Gets Dropped from AQR Capital’s Portfolio

    During the fourth quarter of 2014, AQR Capital closed its position in Shire plc (SHPG). The fund sold its entire stake of 816,116 shares in the company.

    By Stuart McKenzie
  • uploads///Graph
    Company & Industry Overviews

    AbbVie’s Rova-T and the Treatment of Small Cell Lung Cancer

    AbbVie (ABBV) expects to secure FDA (U.S. Food & Drug Administration) approval in the third-line plus small cell lung cancer (or SCLC) indication in 2018.

    By Margaret Patrick
  • uploads///covid  _
    Healthcare

    Gilead Sciences’ COVID-19 Drug Shows Promise

    Today at 7:55 AM ET, Gilead Sciences stock rose by 3.9% to $75.99 in the pre-market session. The company’s remdesivir drug might treat COVID-19.

    By Ambrish Shah
  • uploads///Analysts recommendation
    Company & Industry Overviews

    Analysts Recommendations for AbbVie in August 2017

    Twenty-one analysts were tracking AbbVie in August 2017. Three analysts suggested a “strong buy,” while seven suggested a “buy.”

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    What Do Analysts Recommend for AbbVie?

    Analysts updated their recommendations for AbbVie (ABBV) after the release of its 1Q16 earnings on April 28, 2016.

    By Margaret Patrick
  • uploads///Humira revenues
    Company & Industry Overviews

    AbbVie’s Humira Continues to Generate High Revenues

    In 2Q17, AbbVie’s (ABBV) Humira generated revenues of $4.7 billion, which was a 14.0% rise YoY (year-over-year) and a 15.0% rise QoQ (quarter-over-quarter).

    By Daniel Collins
  • uploads///GUIDANCE
    Company & Industry Overviews

    How’s Gilead Sciences Expected to Perform in 2016?

    Gilead Sciences lowered its guidance for fiscal 2016 due to weak 2Q16 results reported on July 25. It expects its 2016 revenues to be $29.5 billion–$30.5 billion.

    By Sarah Collins
  • uploads///ABT
    Consumer

    Chilton opens a new position in Abbott Laboratories in 4Q13

    Abbott Laboratories (ABT) is a brand new position that accounts for 1.19% of Chilton’s fourth quarter 2013 portfolio.

    By Samantha Nielson
  • uploads///Graph Part  Oct
    Company & Industry Overviews

    Baxalta in the XBI Top Ten Large Caps

    Baxalta (BXLT) rose by 6.2% for the week ending October 16, 2015. The stock rose as it received the Health Canada Approval for OBIZUR.

    By Peter Neil
  • uploads///Chart
    Company & Industry Overviews

    How Eli Lilly’s Cardiovascular Products Have Been Faring

    Eli Lilly and Company’s (LLY) Human Pharmaceutical segment includes cardiovascular products such as Cialis, Effient, and other products.

    By Mike Benson
  • uploads///Graph
    Earnings Report

    What Drove Gilead Sciences’ Hepatitis C Portfolio in 3Q15?

    Gilead Sciences’ (GILD) hepatitis C (or HCV) portfolio is expected to continue driving the company’s revenues and net profit margins in 3Q15.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Celgene’s Operating Expenses in 3Q15

    In 3Q15, Celgene’s gross profit margin improved due to a favorable product mix composed mainly of Revlimid, Pomalyst, and Otezla.

    By Margaret Patrick
  • uploads///pill _
    Earnings Report

    Abbvie Up over 6% on 1Q18 Earnings Beat, Raised Earnings Forecast

    AbbVie (ABBV) released its 1Q18 earnings results for the quarter that ended on March 31 today.

    By Sarah Collins
  • uploads///Graph
    Company & Industry Overviews

    Inside AbbVie’s Analyst Recommendations in 2016

    Based on 24 recommendations, Bloomberg reported that 59.1% of analysts gave AbbVie a “buy” recommendation, while 36.4% of analysts gave the stock a “hold.”

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Humira Continues to Be a Strong Growth Driver for AbbVie in 1Q16

    AbbVie (ABBV) has projected that Humira’s sales in 2016 will be higher than those reported by the drug in 2015 by around 15%–20% in the US.

    By Margaret Patrick
  • uploads///tesla renaissance technologies
    Consumer

    How Did Tesla Become Renaissance Technologies’ Gem?

    In the fourth quarter of 2019, Tesla was Renaissance Technologies’ second-largest holding. Renaissance is one of the largest hedge funds in the US.

    By Rabindra Samanta
  • uploads///johnson and johnson earnings
    Earnings Report

    Will Johnson & Johnson’s Q1 Earnings Improve?

    Johnson & Johnson (NYSE:JNJ) stock has declined by 3.2% since the beginning of 2020. However, the stock has fared better than the broader market.

    By Sirisha Bhogaraju
  • uploads///AdobeStock_
    Healthcare

    AbbVie Stock Lags Biotech Industry—Is It Undervalued?

    AbbVie (ABBV) has returned 2.6% over the past year. AbbVie stock underperformed the US biotech industry, which returned 23.2% over the past year.

    By Oleksandr Pylypenko
  • uploads///Adage
    Financials

    A key overview of Adage Capital’s holdings in 3Q14

    Adage Capital’s US long portfolio grew from $38.69 billion in 2Q14 to $40.2 billion in 3Q14. The portfolio comprised around 699 stocks.

    By Samantha Nielson
  • uploads///KMI
    Energy & Utilities

    Kinder Morgan’s position with Adage Capital eliminated

    Adage Capital exited a position in Kinder Morgan Inc (KMI) in the third quarter. The position accounted for 0.37% of the fund’s total 2Q portfolio.

    By Samantha Nielson
  • uploads///C
    Financials

    Citigroup gets raised position with Adage Capital

    Adage Capital raised its position in Citigroup Inc. (C) in the third quarter. The position accounted for 0.98% of the fund’s total 3Q portfolio.

    By Samantha Nielson
  • uploads///NI
    Energy & Utilities

    Adage Capital raises its position in NiSource

    Adage Capital raised its position in NiSource Inc. (NI) in the third quarter. The position accounted for 0.52% of the fund’s total 3Q14 portfolio.

    By Samantha Nielson
  • uploads///BIDU
    Consumer

    Maverick Capital lowers position in Baidu, Inc.

    Maverick Capital lowered its position in Baidu, Inc. in 3Q14. The position accounts for 0.36% of the fund’s total portfolio in the third quarter.

    By Patricia Garner
  • Healthcare

    The Baupost Group ups its stake in Idenix Pharmaceuticals

    Idenix Pharmaceuticals (IDIX) accounted for a 6.25% position in Baupost’s fourth quarter portfolio. The hedge fund increased its stock holdings in Idenix last month.

    By Samantha Nielson
  • uploads///Graph
    Company & Industry Overviews

    AbbVie Rapidly Advancing Its 2018 Solid Tumor Portfolio

    AbbVie (ABBV) is currently evaluating more than 20 investigational therapies targeting solid tumors. Seventeen of them are in Phase 1 trials.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    AbbVie Expects Peak Sales of $7 Billion for Imbruvica

    AbbVie (ABBV) has projected Imbruvica’s annual revenues to be $5 billion by 2020. That would be driven by a rapid uptake in the first line chronic lymphocytic leukemia (or CLL) segment.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    AbbVie’s Rova-T: Solid Growth Driver for the Future?

    AbbVie (ABBV) aims to position its investigational therapy Rova-T (rovalpituzumab tesirine) as a standard of care treatment for patients with SCLC (small cell lung cancer).

    By Margaret Patrick
  • uploads///SGEN
    Company & Industry Overviews

    Analyzing Seattle Genetics’ Key Collaborations

    Seattle Genetics (SGEN) is focused on maximizing Adcetris’ market reach. Currently, the product is sold in 71 countries.

    By Kenneth Smith
  • uploads///AdobeStock_
    Company & Industry Overviews

    Tesla the Most Profitable Short Bet, Bears Rejoice

    Tesla bears had made a whopping $2.75 billion in mark-to-market gains this year as of August 9, making it the most profitable US short bet year-to-date.

    By Anuradha Garg
  • uploads///Graph
    Company & Industry Overviews

    What Are Mylan’s Key Growth Drivers in Fiscal 2019?

    In fiscal 2018, Mylan (MYL) reported revenues of $11.43 billion, a YoY decline of 4%.

    By Margaret Patrick
  • uploads///business _
    Company & Industry Overviews

    AbbVie Announces Acquisition of Allergan: What You Should Know

    On June 25, AbbVie (ABBV) announced a definitive agreement to acquire Allergan (AGN) in a cash and stock transaction for a total consideration of $63 billion. The deal values Allergan at a 45% premium to its closing price on June 24. AbbVie aims to reduce excessive revenue exposure to Humira through this deal.

    By Margaret Patrick
  • uploads///microscope _
    Company & Industry Overviews

    What to Look for in AbbVie’s Oncology Portfolio in 2019

    According to Evaluate Pharma’s World Preview 2019 report, AbbVie and Johnson & Johnson’s (JNJ) Imbruvica is expected to become the fifth-highest-selling pharmaceutical product in the world by 2024.

    By Margaret Patrick
  • uploads///analysis _
    Company & Industry Overviews

    AbbVie or Allergan: Which Is a Better Pick in June?

    AbbVie (ABBV) is down 14.69%, and Allergan (AGN) is down 13.41% in 2019 on a year-to-date basis. While concerns about the anticipated generic erosion of its flagship Humira franchise have proved to be a drag for AbbVie, Allergan is being increasingly criticized for a couple of reasons.

    By Margaret Patrick
  • uploads///woman _
    Company & Industry Overviews

    How Do Rate Cuts Impact Healthcare Stocks?

    Barclays expects the Fed to cut the rate by 50 basis points in July—three months earlier than previously expected. Barclays expects an additional rate cut by 25 basis points in September.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Comparing AbbVie’s and Amgen’s 2019 Revenue Growth Trajectories

    On its first-quarter earnings conference call, Amgen (AMGN) reduced its revenue guidance to $22.0 billion–$22.9 billion.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    A Look at Cosentyx, Novartis’s Fast-Growing Immunology Drug

    In the first quarter, Novartis’s (NVS) Cosentyx reported net sales of $791 million, a YoY (year-over-year) rise of 41% on a constant currency basis.

    By Margaret Patrick
  • uploads///analysis _
    Company & Industry Overviews

    Analysts Have Mixed Opinions on AbbVie in March

    Wall Street analysts expect a potential upside of 15.38% for AbbVie (ABBV) based on the company’s closing price on March 27.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    ABBV or CELG: Comparing Dividends, Interest Expenses, and Debt

    AbbVie (ABBV) and Celgene (CELG) reported dividends per share of $3.59 and $0.0, respectively, in 2018.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    What Are the Key Growth Drivers for AbbVie in 2019?

    AbbVie (ABBV) expects its leading immunology asset and its hematology-oncology franchise to report growth of close to $1.0 billion in 2019.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    AbbVie or Celgene: Which Is Expected to Report Faster EPS Growth?

    On its fourth-quarter earnings conference call, AbbVie (ABBV) guided for an adjusted gross margin of 82.5% in 2019.

    By Margaret Patrick
  • uploads///bacteria _
    Company & Industry Overviews

    What Analysts Recommend for AbbVie and Celgene This Month

    On February 5, AbbVie (ABBV) closed at $79.69, 1.48% higher than its previous closing price, 5.17% higher than its 52-week low of $75.77.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Imbruvica Is Key Growth Driver for AbbVie in Fiscal 2019

    In the fourth quarter of 2018, AbbVie (ABBV) reported total sales of its hematologic oncology products of $1.13 billion.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Why Humira Revenues in International Markets Are Expected to Fall

    In the fourth quarter of 2018, AbbVie (ABBV) reported Humira’s global sales of $4.92 billion, which is a YoY rise of 0.5% on a reported basis and 1.4% on an operational basis.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Merck or AbbVie: Which Company Returns More Value to Shareholders?

    In the third quarter of 2018, AbbVie authorized an additional share repurchase program worth $5.0 billion.

    By Margaret Patrick
  • uploads///lab _
    Company & Industry Overviews

    Analysts’ Recommendations for Merck & Co. in January

    Based on its closing price on January 10, Merck & Co. had reported returns of 0.59% in the last week and 2.96% in the last quarter.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Venclexta: A Solid Growth Driver for AbbVie in Future Years

    AbbVie (ABBV) reported global Venclexta sales worth $96 million in the third quarter, a YoY (year-over-year) rise of more than 100%.

    By Margaret Patrick
  • uploads///AstraZeneca
    Company & Industry Overviews

    Why Has AstraZeneca’s Stock Price Increased in 2018?

    On November 19, AstraZeneca’s (AZN) stock price closed at $40.80, which represents ~5% growth from its closing price of $38.78 on October 31.

    By Daniel Collins
  • uploads///CLVS
    Company & Industry Overviews

    Gauging Analysts’ Views on Clovis Stock

    In November, of the 12 analysts covering Clovis Oncology (CLVS) stock, seven have given it “buy” or higher ratings, and five have given it “hold” ratings.

    By Kenneth Smith
  • uploads///Imbruvica
    Company & Industry Overviews

    A Performance Overview of JNJ’s Imbruvica, Velcade, and Zytiga

    Johnson & Johnson’s (JNJ) Imbruvica generated revenue of $705.0 million in the third quarter.

    By Daniel Collins
  • uploads///analysis _
    Earnings Report

    What to Expect from Thermo Fisher’s Third-Quarter Earnings

    Thermo Fisher Scientific (TMO), a leading life sciences company, is scheduled to release its third-quarter earnings on October 24.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Novartis’s Sandoz Business Has Been Performing Recently

    Sandoz, Novartis’s (NVS) generics business, is a market leader in differentiated generics.

    By Mike Benson
  • uploads///Chart
    Healthcare

    How Did Pharmaceutical ETFs Perform in Q3 2018?

    The Healthcare Select Sector SPDR ETF’s (XLV) price has increased ~14.6% in the third quarter, and its year-to-date returns increased ~15.5% on October 2.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Pfizer’s Earnings Quality and Dividend Performance

    Pfizer’s dividend yield is 3.09%. Its dividend yield last year was 3.53%, and its five-year average yield is 3.44%.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Does Sage Therapeutics’ Product Portfolio Look in September?

    Sage Therapeutics’ (SAGE) product portfolio includes products under development for the treatment of various rare and life-threatening central nervous system disorders.

    By Mike Benson
  • uploads///TSRO
    Company & Industry Overviews

    Here’s What Tesaro’s Valuation Trend Indicates

    Tesaro stock has been on a downward trajectory for the past 52 weeks. From a high of $135 on September 5, 2017, it has corrected to $27 in August.

    By Kenneth Smith
  • uploads///syringe _
    Company & Industry Overviews

    Gauging Analysts’ Expectations for Novavax and Peers in August

    Novavax has entered into a key grant agreement with the Bill and Melinda Gates Foundation, which is the current source of its revenue.

    By Kenneth Smith
  • uploads///checklist _
    Earnings Report

    How Baxter International Fared in the Second Quarter

    Baxter’s gross profit increased from $1.13 billion in Q2 2017 to $1.24 billion in Q2 2018.

    By Kenneth Smith
  • uploads///hand _
    Earnings Report

    Eli Lilly Surpasses Estimates, Reports Growth in Q2 2018

    In Q2 2018, Eli Lilly’s (LLY) revenue rose 9% YoY (year-over-year) to ~$6.4 billion.

    By Mike Benson
  • uploads///PART  Direxion
    Healthcare

    Biotech Sector Continue to Dazzle Despite Market Distress

    Biotech stocks—with their binary outcomes and potential FDA approvals or denials—should whip around, pending various outcomes.

    By Direxion
  • uploads///ABBV
    Company & Industry Overviews

    What’s AbbVie’s Business Strategy for 2018?

    AbbVie (ABBV) has steadily increased its dividend rate. In October 2017, the company announced an increase in its quarterly dividend.

    By Kenneth Smith
  • uploads///HCV franchise
    Earnings Report

    AbbVie’s Hepatitis C Franchise, Kaletra, and Synagis in 1Q18

    In 1Q18, AbbVie’s (ABBV) HCV (hepatitis C virus) franchise generated revenues of $919 million.

    By Daniel Collins
  • uploads///Duodopa
    Company & Industry Overviews

    AbbVie’s Duodopa, Creon, Synagis, Synthroid, and Sevoflurane

    In 4Q17, AbbVie’s (ABBV) Duodopa generated revenue of $100 million, marking ~28% growth YoY (year-over-year) and 6% growth quarter-over-quarter.

    By Daniel Collins
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.